好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Severe Cerebellar Syndrome Improved with Plasma Exchanges in Patient with Lung Adenocarcinoma Treated with Durvalumab
Autoimmune Neurology
P1 - Poster Session 1 (5:30 PM-6:30 PM)
1-004
We describe a patient with lung adenocarcinoma treated with Durvalumab, whose disabling ocular and bulbar symptoms and severe truncal ataxia improved with plasma exchanges carefully timed with immunotherapy for cancer. 

Durvalumab is a monoclonal antibody that blocks the interaction of programmed cell death ligand (PD-L1) with PD-1 molecules. It has shown significant survival benefits in various cancers as an immune checkpoint inhibitor. With increased usage of this therapy, there has been reported neurological predilection for immune-related adverse effects from checkpoint inhibitor neurotoxicity. 

An index patient with metastatic lung adenocarcinoma and severe cerebellar syndrome is identified and therapeutic challenges described.
A fifty-eight year old, African American woman presented with three months of oscillopsia, dizziness, scanning speech, and severe truncal ataxia. She was found to have stage IIIA lung adenocarcinoma. Brain MRI demonstrated abnormal T2/FLAIR signal in bilateral cerebellar hemispheres with lack of enhancement consistent with paraneoplastic involvement. No distinct paraneoplastic antibody was identified. She received pulse-dose steroids and IVIg with no improvement of cerebellar syndrome. A month later, she started chemotherapy and radiation therapy with transient cancer regression.  

 

Because of metastatic spread, Durvalumab was initiated. She completed four doses that was complicated by worsening cerebellar symptoms and autoimmune colitis. During Durvalumab holiday, she received two courses of 5 PLEX treatments, two months apart, along with vigorous physical and speech therapy. Her neurologic symptoms and functional status improved considerably. At present time, patient is largely independent for ADLs and uses a walker. Repeat brain MRI revealed resolution of previously seen abnormalities. 

Checkpoint inhibitors may worsen concomitant paraneoplastic neurologic syndromes that develop in association with malignancies potentially responsive to PD-L1 and PD-1 inhibitors. Meticulous timing of life-saving immune therapies for cancer with effective immune treatments for an underlying or associated neurological syndrome is essential for best outcomes.
Authors/Disclosures
Connie G. Tang, MD (Lehigh Valley Health Network)
PRESENTER
Dr. Tang has nothing to disclose.
No disclosure on file
Goran Rakocevic, MD, FAAN (Thomas Jefferson University) Dr. Rakocevic has nothing to disclose.